Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation
Ananda S. Mirchandani(Clinical Trial Investigators), Sarah R. Walmsley(Centre for Inflammation Research), A. John Simpson(Newcastle upon Tyne Hospitals NHS Foundation Trust), Emily Watts(Centre for Inflammation Research), Manuel A. Sánchez-García(Queen's Medical Centre), Fiona Murphy(Centre for Inflammation Research), David Griffith(Queen's Medical Centre), David H. Dockrell(NHS Lothian), Christos Spanos(Wellcome Centre for Cell Biology), Anthony Rostron(Newcastle University), Christopher W. Pugh(University College London), Liam Delaney(Queen's Medical Centre), Jürgen Schwarze(University of Freiburg), Kathryn Musgrave(Newcastle upon Tyne Hospitals NHS Foundation Trust), Leila Reyes(Queen's Medical Centre), Pranvera Sadiku(University of Edinburgh), J. Kenneth Baillie(NHS Lothian), Clare Pridans(Centre for Inflammation Research), Tony Ly(University of Dundee), Nick Parkinson(Roslin Institute), I. Harper(Queen's Medical Centre), Hannah Lawson(University of London), Simone Arienti(Queen's Medical Centre), Kamil R. Kranc(Queen Mary University of London), George Cooper(Queen's Medical Centre), Calum C. Bain(MRC Centre for Regenerative Medicine), Stuart J. Forbes(MRC Centre for Regenerative Medicine), Tyler Morrison(Queen's Medical Centre), Peter J. Ratcliffe(University of Oxford), Sara Clohisey(Roslin Institute), Lara Campana(MRC Centre for Regenerative Medicine), Moira K. B. Whyte(University of Edinburgh), Philip Starkey Lewis(MRC Centre for Regenerative Medicine), Jonathan Scott(Newcastle University), Van Kelly(Wellcome Centre for Cell Biology), Sarah A. Clark(NHS Lothian), David Lewis(Wellcome Centre for Cell Biology), Patrícia Coelho(Queen's Medical Centre), Nikhil Hirani(Centre for Inflammation Research), Stephen J. Jenkins(Centre for Inflammation Research), Rebecca Dickinson(Queen's Medical Centre), Ailiang Zhang(Soochow University)
Cited by 79
Related Papers
An atlas of active enhancers across human cell types and tissues
|Nature|2014|2.8k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k